Etanercept: efficacy and safety for approved indications.
about
Inflammatory cascades driven by tumor necrosis factor-alpha play a major role in the progression of acute liver failure and its neurological complicationsEtanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-α-induced inflammation and bone loss.Comparative Biochemical and Functional Analysis of Viral and Human Secreted Tumor Necrosis Factor (TNF) Decoy Receptors.Evolution of Pediatric Chronic Disease Treatment Decisions: A Qualitative, Longitudinal View of Parents' Decision-Making ProcessNodular Vasculitis That Developed during Etanercept (Enbrel) Treatment in a Patient with Psoriasis.Arthritis gene therapy and its tortuous path into the clinic.Tumor Necrosis Factor-α: Life and Death of Hepatocytes During Liver Ischemia/Reperfusion Injury.Matrix metalloproteinase 13 modulates intestinal epithelial barrier integrity in inflammatory diseases by activating TNF.Progression of luminal breast tumors is promoted by ménage à trois between the inflammatory cytokine TNFα and the hormonal and growth-supporting arms of the tumor microenvironmentSchizophrenia-like disorder associated with etanercept treatment.Inhibition of tumor necrosis factor alpha reduces the outgrowth of hepatic micrometastasis of colorectal tumors in a mouse model of liver ischemia-reperfusion injury.Microenvironmental networks promote tumor heterogeneity and enrich for metastatic cancer stem-like cells in Luminal-A breast tumor cells.Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritisEtanercept-induced injection site reactions: potential pathomechanisms and clinical assessment.Chronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review.The risk of deep fungal infections during biologic therapy for psoriasis.Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics.An Update on Medical Treatment Options for Hidradenitis Suppurativa.Immediate neurological recovery following perispinal etanercept years after brain injury.Primary varicella infection in children with systemic juvenile idiopathic arthritis under tocilizumab therapy.Incidence of herpes zoster infections in juvenile idiopathic arthritis patients.Influence of etanercept on leptin and ghrelin secretion in children with juvenile idiopathic arthritis.Cardiovascular risk evaluation through heart rate variability analysis in psoriatic patients before and after 24 weeks of etanercept therapy: Prospective study.Apoptotic enteropathy caused by antimetabolites and TNF-α antagonists.Selective TNF inhibition for chronic stroke and traumatic brain injury: an observational study involving 629 consecutive patients treated with perispinal etanercept.A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.Educational session as a tool to increase patient satisfaction of switching etanercept from the prefilled syringe to the autoinjection pen.Cost-Effectiveness Analysis of First-Line Treatment With Biologic Agents in Polyarticular Juvenile Idiopathic Arthritis.Histiocytoid Sweet syndrome successfully treated with etanercept.
P2860
Q28485217-7DD8A7D0-E5EA-455D-9546-50DE43DEB895Q30009390-0AD63E2B-22CE-4242-BB75-BD26AEDD377DQ35783059-7FFF41BB-F05B-471E-BFC6-A82E581C2E9BQ36200559-E176753A-070B-4042-9F45-01B080500C88Q36214266-D3DE46FC-C837-4322-BB1E-2332B64A9764Q36698181-85AA224C-3214-420F-A47D-2C1AB0BCB9AEQ36701541-C46FF691-E37E-444C-BB46-49182C391B3BQ37040818-32C70271-F13F-40DF-9B1C-232BD53B05ABQ37402928-B5BBC6AA-C245-481E-81FF-2EE2D5EBBA6BQ37516694-3B6542E3-14B4-4B60-B2E6-E470AEE943F4Q37516970-680225EF-659A-48A8-8858-3BEAA38CA4FBQ37697134-1FCFCB6B-1BE8-4E1D-9BCB-86697B2743FAQ37724124-7FC20E12-3BD6-4F80-98F5-8D6A379F591AQ38045471-79530B7B-4FC1-4911-B3FF-C8EB7CFC93D2Q38201788-64958E94-633A-47E8-BE0C-D3B0FADEF7D0Q38219217-3E9035D5-0700-4B1C-8AF3-5A8D814686FAQ38645738-AEAFBB35-88CE-4075-99C1-72C40FDD8DECQ38667207-043AF651-A5F0-4C33-99AF-16632CE7C7AFQ39209875-3AB733F0-A462-47B3-A189-2D6F661E6B8CQ40450982-E058C9C2-9254-4F41-94B6-35CE112E29EDQ41547963-B1853C1E-CE28-42B0-B54D-ED2A01E00DB4Q41813478-49338E11-36E4-48FF-98D5-41D4CCEC882BQ41829124-B3AC2D7B-8796-46AF-840B-8AB372DACCCCQ42225292-561F0A0A-CD9F-40CF-9BAF-5B30D74DADB0Q42674268-109C3D56-72AB-4C6E-B71A-83CABBFFE404Q46483294-29C77E9F-8B24-4C56-966C-3A4CF47578AEQ46889192-3BB50D51-A42A-4FE2-91CD-F180FC63DE92Q51759532-068889E5-DBD3-4AC9-B0B7-FD78C60805F3Q55063888-2839796E-56E1-455C-8F64-A4BC58CF05DE
P2860
Etanercept: efficacy and safety for approved indications.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Etanercept: efficacy and safety for approved indications.
@en
Etanercept: efficacy and safety for approved indications.
@nl
type
label
Etanercept: efficacy and safety for approved indications.
@en
Etanercept: efficacy and safety for approved indications.
@nl
prefLabel
Etanercept: efficacy and safety for approved indications.
@en
Etanercept: efficacy and safety for approved indications.
@nl
P2093
P2860
P1476
Etanercept: efficacy and safety for approved indications.
@en
P2093
Alice B Gottlieb
Shimrat Yaniv
Shiu-chung Au
Todd A Kerensky
P2860
P304
P356
10.1517/14740338.2012.633509
P407
P577
2011-11-11T00:00:00Z